Cargando…

Evidences of CTLA-4 and PD-1 Blocking Agents-Induced Cardiotoxicity in Cellular and Preclinical Models

Background: Several strategies based on immune checkpoint inhibitors (ICIs) have been developed for cancer therapy, opening to advantages in cancer outcomes. However, several ICI-induced side effects have emerged in these patients, especially a rare but clinically significant cardiotoxicity with hig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Quagliariello, Vincenzo, Passariello, Margherita, Rea, Domenica, Barbieri, Antonio, Iovine, Martina, Bonelli, Annamaria, Caronna, Antonietta, Botti, Gerardo, De Lorenzo, Claudia, Maurea, Nicola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7711520/ https://www.ncbi.nlm.nih.gov/pubmed/33086484 http://dx.doi.org/10.3390/jpm10040179

Ejemplares similares

SARS-CoV-2 Infection and Cardioncology: From Cardiometabolic Risk Factors to Outcomes in Cancer Patients
por: Quagliariello, Vincenzo, et al.
Publicado: (2020)

NLRP3 as Putative Marker of Ipilimumab-Induced Cardiotoxicity in the Presence of Hyperglycemia in Estrogen-Responsive and Triple-Negative Breast Cancer Cells
por: Quagliariello, Vincenzo, et al.
Publicado: (2020)

Polydatin Reduces Cardiotoxicity and Enhances the Anticancer Effects of Sunitinib by Decreasing Pro-Oxidative Stress, Pro-Inflammatory Cytokines, and NLRP3 Inflammasome Expression
por: Quagliariello, Vincenzo, et al.
Publicado: (2021)

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
por: Heinzerling, Lucie, et al.
Publicado: (2016)

The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
por: Quagliariello, Vincenzo, et al.
Publicado: (2021)

Cardiotoxic effects of the novel approved anti-ErbB2 agents and reverse cardioprotective effects of ranolazine
por: De Lorenzo, Claudia, et al.
Publicado: (2018)

Cardioprotective Effects of Nanoemulsions Loaded with Anti-Inflammatory Nutraceuticals against Doxorubicin-Induced Cardiotoxicity
por: Quagliariello, Vincenzo, et al.
Publicado: (2018)

Antineoplastic-related cardiotoxicity, morphofunctional aspects in a murine model: contribution of the new tool 2D-speckle tracking
por: Coppola, Carmela, et al.
Publicado: (2016)

Combination of Spirulina platensis, Ganoderma lucidum and Moringa oleifera Improves Cardiac Functions and Reduces Pro-Inflammatory Biomarkers in Preclinical Models of Short-Term Doxorubicin-Mediated Cardiotoxicity: New Frontiers in Cardioncology?
por: Quagliariello, Vincenzo, et al.
Publicado: (2022)

New Insights on the Role of Anti-PD-L1 and Anti-CTLA-4 mAbs on Different Lymphocytes Subpopulations in TNBC
por: Lembo, Rosa Rapuano, et al.
Publicado: (2022)

PCSK9 Inhibitors in Cancer Patients Treated with Immune-Checkpoint Inhibitors to Reduce Cardiovascular Events: New Frontiers in Cardioncology
por: Quagliariello, Vincenzo, et al.
Publicado: (2023)

Nano-Encapsulation of Coenzyme Q10 in Secondary and Tertiary Nano-Emulsions for Enhanced Cardioprotection and Hepatoprotection in Human Cardiomyocytes and Hepatocytes During Exposure to Anthracyclines and Trastuzumab
por: Quagliariello, Vincenzo, et al.
Publicado: (2020)

Can Beta-2-Adrenergic Pathway Be a New Target to Combat SARS-CoV-2 Hyperinflammatory Syndrome?—Lessons Learned From Cancer
por: Barbieri, Antonio, et al.
Publicado: (2020)

Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways
por: Quagliariello, Vincenzo, et al.
Publicado: (2022)

Corrigendum: Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways
por: Quagliariello, Vincenzo, et al.
Publicado: (2023)

Inhibition of tumor growth by cancer vaccine combined with metronomic chemotherapy and anti-PD-1 in a pre-clinical setting
por: Petrizzo, Annacarmen, et al.
Publicado: (2017)

Multiple Effects of Ascorbic Acid against Chronic Diseases: Updated Evidence from Preclinical and Clinical Studies
por: Berretta, Massimiliano, et al.
Publicado: (2020)

Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule
por: Berezhnoy, Alexey, et al.
Publicado: (2020)

Novel Combinations of Human Immunomodulatory mAbs Lacking Cardiotoxic Effects for Therapy of TNBC
por: Vetrei, Cinzia, et al.
Publicado: (2021)

Targeting CD47 Enhances the Efficacy of Anti-PD-1 and CTLA-4 in an Esophageal Squamous Cell Cancer Preclinical Model
por: Tao, Hua, et al.
Publicado: (2017)

Engineering a Smart Agent for Enhanced Immunotherapy Effect by Simultaneously Blocking PD‐L1 and CTLA‐4
por: Jiang, Chunjuan, et al.
Publicado: (2021)

Immune Checkpoint PD-1/PD-L1 CTLA-4/CD80 are Blocked by Rhus verniciflua Stokes and its Active Compounds
por: Li, Wei, et al.
Publicado: (2019)

Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV(+) oral cancer
por: Dorta-Estremera, Stephanie, et al.
Publicado: (2019)

Durable Responses to Anti-PD1 and Anti-CTLA4 in a Preclinical Model of Melanoma Displaying Key Immunotherapy Response Biomarkers
por: Shklovskaya, Elena, et al.
Publicado: (2022)

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
por: Callahan, Margaret K., et al.
Publicado: (2015)

Combination of CTLA-4 and PD-1 blockers for treatment of cancer
por: Rotte, Anand
Publicado: (2019)

Inborn Errors of Immunity and Their Phenocopies: CTLA4 and PD-1
por: Hao, Yuwei, et al.
Publicado: (2022)

Anti-CTLA-4 and anti-PD-1 immunotherapies repress tumor progression in preclinical breast and colon model with independent regulatory T cells response
por: Rupp, Tristan, et al.
Publicado: (2022)

Isolation of Two Novel Human Anti-CTLA-4 mAbs with Intriguing Biological Properties on Tumor and NK Cells
por: Passariello, Margherita, et al.
Publicado: (2020)

Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models
por: Jure-Kunkel, Maria, et al.
Publicado: (2013)

Peptide Blocking CTLA-4 and B7-1 Interaction
por: Podlesnykh, Stepan V., et al.
Publicado: (2021)

CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
por: Buchbinder, Elizabeth I., et al.
Publicado: (2016)

Expression of PD‐L1 and CTLA‐4 in female urethral carcinoma
por: Ninomiya, Sahoko, et al.
Publicado: (2018)

CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma
por: Guo, Xiao-Jun, et al.
Publicado: (2021)

PD-L1/PD-1 and CTLA-4 Expression in Equine Penile Squamous Cell Carcinomas
por: Porcellato, Ilaria, et al.
Publicado: (2021)

ODP342 Panhypopituitarism Induced by CTLA-4 and PD-1/PD-L1 Inhibitor Immunotherapy
por: Hernandez-Cordero, Nicole, et al.
Publicado: (2022)

Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth
por: Parra, Karla, et al.
Publicado: (2017)

Clinical and preclinical evidence of sex-related differences in anthracycline-induced cardiotoxicity
por: Meiners, Becky, et al.
Publicado: (2018)

Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1
por: D’Alterio, Crescenzo, et al.
Publicado: (2019)

Immunomodulatory mAbs as Tools to Investigate on Cis-Interaction of PD-1/PD-L1 on Tumor Cells and to Set Up Methods for Early Screening of Safe and Potent Combinatorial Treatments
por: Vetrei, Cinzia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0l436e3lqavemikgh4olcpq03e